Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

How Is Donor Tissue Tested Before Being Used in Stem Cell Therapy?

Written by Dr. David Greene, MD, PhD, MBA on June 11, 2026

Table of Contents

If you are considering a stem cell procedure, one of the most important questions you can ask is: How can I be sure the donor tissue is safe? The answer involves a federally regulated, multi-step process that begins long before any product reaches a clinic.

This article explains how umbilical cord tissue is screened, tested, and cleared for clinical use — and what FDA standards govern every stage.

Where Does the Donor Tissue Come From?

Most allogeneic stem cell procedures use tissue recovered from umbilical cords donated at birth. This tissue — including Wharton’s jelly, a gelatinous substance inside the cord — is rich in mesenchymal stem cells (MSCs) with well-documented anti-inflammatory and regenerative properties.

Tissue is collected at delivery from consenting mothers, who donate what would otherwise be medical waste. Collection companies must be FDA-registered and accredited by bodies such as the American Association of Tissue Banks (AATB). R3 Stem Cell sources all donor tissue exclusively from suppliers that meet these standards.

Layer One: Donor Screening

Before any tissue is collected, the donor mother completes a detailed medical and lifestyle questionnaire. The FDA requires all HCT/P donors to be screened for relevant communicable disease agents and diseases, with a donor eligibility determination made before product distribution under 21 CFR Part 1271 Subpart C.

Key screening variables include:

  • Personal and family cancer history
  • Smoking status
  • Recent international travel
  • Tattoos or piercings
  • Intravenous drug use history
  • Recent live-virus vaccinations

 

Any donor flagged as elevated risk is disqualified. Patients wanting the full regulatory context can review how the FDA classifies human cell and tissue-based products under the 351 vs. 361 framework.

Layer Two: Infectious Disease Testing

Maternal blood is laboratory-tested using FDA-licensed assays for a mandated panel of communicable diseases. Testing covers HIV-1, HIV-2, hepatitis B and C, syphilis, Chagas disease, HTLV-1 and HTLV-2, and CMV. Nucleic acid testing for HIV, HBV, West Nile virus, and HCV is also performed, with Zika virus screening conducted where indicated.

FDA-Mandated Disease Testing Panel

Pathogen

Type

Method

HIV-1 / HIV-2

Virus

Antibody + NAT

Hepatitis B (HBV)

Virus

Antigen, antibody + NAT

Hepatitis C (HCV)

Virus

Antibody + NAT

Syphilis

Bacteria

Serological

West Nile Virus

Virus

NAT

Chagas Disease

Parasite

Antibody

CMV

Virus

Antibody

HTLV-1 / HTLV-2

Virus

Antibody

Zika Virus

Virus

NAT (where indicated)

No HCT/P may be implanted, transplanted, infused, or transferred until the donor has been formally determined eligible under 21 CFR Part 1271. This is a hard regulatory requirement. For more on how the FDA oversees the stem cell industry, that oversight is most concretely expressed through these mandatory testing standards.

Layer Three: Post-Processing Product Testing

After the tissue is processed and prepared for clinical use, the finished product undergoes a final round of microbiological testing before release. Release testing includes cell count, viability, endotoxin levels, mycoplasma, Gram stain, and sterility — and the product is only cleared for use if all criteria are met.

This panel covers:

Bacterial cultures (aerobic and anaerobic)

Fungal cultures

Viral screening

Endotoxin testing — bacterial endotoxins are lipopolysaccharides from Gram-negative bacteria capable of inducing dangerous fever responses, and their presence in a biological product poses a serious patient safety risk even after sterilization.

Any batch that fails is discarded. Patients often ask whether umbilical cord tissue retains live stem cells after this process — an important question directly tied to how processing and cryopreservation are handled.

Why Each Layer Matters

Each testing layer targets a different point of risk:

Donor screening — eliminates known risk factors before collection

Infectious disease testing — confirms no active pathogens at the time of collection

Post-processing testing — ensures no contamination was introduced during manufacturing

The FDA periodically identifies new communicable disease agents and updates testing requirements through Guidance for Industry publications, so the framework evolves alongside emerging biological threats.

When comparing autologous versus allogeneic stem cell options, this standardized, documented testing chain is one of the strongest arguments for well-regulated allogeneic umbilical cord products.

About R3 Stem Cell

R3 Stem Cell operates more than 80 centers across seven countries and has performed over 28,000 procedures. Free consultations are available for patients exploring treatment options. All products are sourced from FDA-registered, accredited suppliers whose screening, testing, and release standards meet or exceed federal requirements.

Frequently Asked Questions

Who regulates donor tissue used in stem cell therapy?

The FDA regulates all human cell and tissue-based products (HCT/Ps) under 21 CFR Part 1271. Any company collecting, processing, or distributing donor tissue for clinical use must be registered with the FDA and comply with these federal standards. Additional accreditation from the American Association of Tissue Banks (AATB) is also required by reputable suppliers.

What diseases are donors tested for before tissue is used?

Donor mothers are lab-tested for HIV-1 and HIV-2, Hepatitis B and C, syphilis, Chagas disease, HTLV-1 and HTLV-2, CMV, West Nile virus, and Zika virus (where indicated). Both antibody-based assays and nucleic acid testing (NAT) are used to ensure accuracy.

Is umbilical cord tissue safe to use in stem cell procedures?

When sourced from an FDA-registered, AATB-accredited supplier and processed under current Good Tissue Practice (cGTP) standards, umbilical cord tissue undergoes rigorous multi-layer screening. Each finished product batch must pass bacterial, fungal, viral, and endotoxin testing before it can be released for clinical use.

What is endotoxin testing and why does it matter?

Endotoxin testing measures the presence of lipopolysaccharides — toxic compounds released by Gram-negative bacteria. Even if a product appears sterile, residual endotoxins can trigger dangerous fever responses in patients. Every batch of finished stem cell product must pass endotoxin limits before it is approved for clinical use.

Contact Us

Stem cell therapy for diabetes is not yet a standard of care in most countries and is generally considered investigational or complementary. Patients should review FDA regulations on cell therapies for context.

The shift in thinking began with a significant clinical study from Stanford University, published in Stroke in 2016. Researchers injected mesenchymal stem cells directly into the brains of chronic stroke patients through surgically drilled openings. The results were striking — patients who were years past their strokes showed measurable improvements in motor function, with no serious adverse events linked to the stem cells.

A follow-up phase 2b trial confirmed both the safety profile and the continued functional benefit.

The key finding was not just that patients improved — it was when they improved. These were patients well outside the traditional recovery window, which proved that the brain retains the capacity to respond to regenerative signals long after injury. To understand more about how stem cell therapy works at the biological level, it helps to look at the signaling and repair mechanisms that make these results possible.

Why Dr. Hector is "Passionate" About the Word "Natural"

Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes:

What Does the Bioethics Community Say?